Tenaya's Gene Therapy Data Signals New Hope for Genetic Heart Disease

SOUTH SAN FRANCISCO, CA – December 11, 2025 – In a significant development for the field of cardiac gene therapy, Tenaya Therapeutics (NASDAQ: TNYA) today announced positive interim data from its RIDGE-1 clinical trial for TN-401. The results suggest the investigational therapy is not only well-tolerated but also shows early signs of efficacy in treating arrhythmogenic right ventricular cardiomyopathy (ARVC), a severe, inherited heart condition. For the more than 70,000 people in the U.S. living with the PKP2-associated form of the disease, this news represents a potential shift from lifelong symptom management to a one-time, disease-modifying treatment.

The announcement provides a crucial, early validation of Tenaya's platform and has sent a clear signal to investors that the high-risk, high-reward pursuit of a genetic cure for heart disease may be moving closer to reality. The initial data from the first three patients treated at a low dose offers a compelling glimpse into a future where the underlying cause of a devastating cardiac condition can be addressed directly.

A Potential Cure Encoded in a Virus

ARVC caused by mutations in the plakophilin-2 (PKP2) gene is a progressive and life-threatening condition. It leads to the replacement of healthy heart muscle with fibrofatty tissue, causing dangerous arrhythmias and placing patients, who are often diagnosed before age 40, at high risk for sudden cardiac arrest. Current treatments, such as anti-arrhythmic drugs and implantable cardioverter-defibrillators (ICDs), manage symptoms and prevent death but do nothing to halt the disease's relentless progression.

Tenaya’s TN-401 is designed to fundamentally alter this trajectory. The therapy uses a well-established adeno-associated virus vector (AAV9), chosen for its natural ability to target heart muscle cells, to deliver a functional copy of the PKP2 gene. The goal is to restore the production of the critical PKP2 protein, which is essential for maintaining the structural integrity and electrical signaling of the heart.

The interim data from the first cohort of the RIDGE-1 trial, while early, is highly encouraging. In the first two patients with sufficient follow-up, the therapy led to a significant reduction in arrhythmia burden - a key indicator of disease activity. One patient saw a 46% decrease in premature ventricular contractions (PVCs), while another experienced a remarkable 89% reduction. That same patient, who had a high burden of non-sustained ventricular tachycardias (NSVTs) at baseline, saw them drop to zero.

Crucially, these clinical improvements are supported by biopsy data showing the therapy is working as designed. The first two patients showed robust gene delivery to the heart and a corresponding mean increase of 10% in PKP2 protein levels just eight weeks after dosing.

“We are excited by the strength of the data for TN-401 at this relatively early timepoint in the RIDGE-1 trial,” said Whit Tingley, M.D., Ph.D., Tenaya’s Chief Medical Officer. “Less than a year after dosing, initial data indicate a promising safety profile, consistent transduction of the gene therapy in cardiomyocytes and RNA and protein expression, and meaningful reductions in PVCs and NSVTs, well-established risk factors for dangerous sustained arrhythmias.”

Clearing a Critical Safety Hurdle

For any gene therapy, and especially for those targeting a vital organ like the heart, the safety profile is paramount. High-dose AAV therapies have historically faced scrutiny over potential toxicities, making the safety results from the TN-401 trial a critical focus for both regulators and investors. On this front, Tenaya's initial data provides a strong measure of confidence.

TN-401 was reported as well-tolerated at the 3E13 vg/kg dose level, with no dose-limiting toxicities observed. Most adverse events were mild and deemed unrelated to the treatment. One serious adverse event was reported - a transient, asymptomatic elevation in cardiac troponin levels - but it was categorized as serious only because it required inpatient monitoring, and it resolved without issue. Importantly, no instances of more severe AAV-associated toxicities, such as thrombotic microangiopathy (TMA) or other cardiotoxicities, were observed. Furthermore, all three patients have successfully tapered off the immunosuppressive medicines required during the initial treatment period, a positive indicator for the therapy's long-term tolerability.

This favorable safety profile builds on positive recommendations from an independent Data Safety and Monitoring Board (DSMB) earlier in the year, reinforcing a consistent narrative that Tenaya is successfully navigating one of the biggest challenges in the gene therapy space.

Sizing the Market and Competitive Edge

The commercial opportunity for a first-in-class, potentially curative therapy for PKP2-associated ARVC is substantial. The condition's classification as an orphan disease, affecting an estimated one in 2,000 to 5,000 people, creates a focused market with a high unmet need. For a one-time therapy that could replace a lifetime of medical management and ICD maintenance, the value proposition is immense.

While Tenaya is not entirely alone in the pursuit of a genetic treatment for ARVC, its progress in the clinic provides a significant first-mover advantage. The positive human data announced today sets a high bar for any competitors following behind. This clinical success also provides a halo effect for Tenaya’s broader pipeline, which includes another gene therapy candidate, TN-201 for hypertrophic cardiomyopathy (HCM), and a small molecule drug for heart failure. This demonstrates a strategic, multi-pronged approach to tackling heart disease that diversifies risk and expands the company's long-term potential.

Navigating the Fast Track to Approval

Recognizing the profound unmet need in ARVC, the U.S. Food and Drug Administration has granted TN-401 both Orphan Drug and Fast Track designations. These designations are more than just accolades; they provide tangible benefits that can accelerate the path to market, including more frequent communication with the FDA, eligibility for priority review, and seven years of market exclusivity upon approval.

This streamlined regulatory pathway is a key strategic asset. With the low-dose cohort showing promising results, all eyes now turn to the trial's second cohort, which is receiving a higher dose of 6E13 vg/kg. Dosing in this cohort is already complete, and the data, when it becomes available, will be a critical inflection point. Investors and clinicians will be watching closely to see if a higher dose can produce an even more profound and durable effect on protein expression and arrhythmia reduction, without compromising the excellent safety profile seen thus far.

The journey from a promising interim result to an approved therapy is long, but Tenaya Therapeutics has successfully navigated a crucial early step. Today’s data provides not just hope for patients but also a compelling case study in the strategic development of cutting-edge therapies, marking the company as a key innovator to watch in the evolving landscape of modern medicine.